OSLO, Norway--(BUSINESS WIRE)--Reference is made to the announcement published on 16 September 2014 in which Nordic Nanovector AS (the “Company”) announced the final result of its subsequent repair offering (the "Offering").
The share capital increase related to the issuance of the new shares in connection with the Offering has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 4,964,275 divided into 24,821,375 shares, each with a nominal value of NOK 0.2. The new shares can from now on be traded on the NOTC.
About Nordic Nanovector
AS Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
This information was brought to you by Cision http://news.cision.com